Ainos, Inc. (as identified in request) — filing summary
Filing identity: The supplied Form 10-Q is for Amarillo Biosciences, Inc. (ABI), not Ainos, Inc. It covers the quarter and nine months ended September 30, 2015; the financial statements are unaudited.
Business context and reporting period
ABI develops biologics, with a historical focus on low-dose oral human interferon for potential human-disease treatments. It reported no product revenue. The company emerged from Chapter 11 in January 2015 and adopted fresh-start accounting effective November 20, 2014. The filing cautions that successor-period results are not directly comparable with predecessor-period results.
Financial results and liquidity
- Revenue: $0 for both the third quarter and first nine months of 2015 and the comparable 2014 periods.
- Third quarter: Operating expenses and operating loss were $113,552, versus $103,747 in Q3 2014. Net loss was $114,148, versus $104,337. Basic and diluted loss per share was $0.01.
- Nine months: Operating expenses and operating loss were $327,473, versus $464,965 in 2014. Net loss was $329,087, versus $466,285. Basic and diluted loss per share was $0.02.
- Cash flow: Operating activities used $89,104 in cash in the first nine months of 2015; investing activities used $11,578. No financing cash flow was reported for that period. Cash declined by $100,682, from $318,556 at year-end 2014 to $217,874 at September 30, 2015.
- Balance sheet and liquidity: Current assets were $252,555 and current liabilities $614,722, a working-capital deficit of $362,167. Total liabilities were $614,722, against total assets of $335,468; stockholders’ deficit was $279,254.
- Debt: Related-party notes payable totaled $384,555, all classified as current at September 30, 2015. Related-party accounts payable were $144,426. ABI said a $37,811 installment on its secured Yang Group note, due September 1, 2015, had not been paid; no demand had been made.
- Margins: With no revenue or cost of revenue, gross margin was zero; operating and net margins are not meaningful.
Changes versus the prior comparable period
Q3 SG&A increased 9% to $113,552, mainly due to salary expense. For the nine-month period, SG&A fell 27% to $327,473, mainly because of lower professional fees and reorganization expenses; R&D was $0 versus $15,270 in 2014. Nine-month net loss decreased 29%, but the filing notes that fresh-start accounting makes predecessor and successor periods not directly comparable. The working-capital deficit improved from $5,361,214 at September 30, 2014 to $362,167 at September 30, 2015.
Outlook, risks, and unusual items
- Management estimated post-reorganization financing needs of $1.0 million to $1.6 million. Yang Group members had indicated willingness to assist, but were not obligated to provide financing. Management said burn rate was difficult to estimate while budgets were being developed and new revenue streams had not materialized.
- ABI anticipated that commercialization or development efforts, if undertaken, would not produce meaningful revenue before Q4 2016 or possibly later. It did not provide formal earnings guidance.
- The company disclosed substantial doubt about its ability to continue as a going concern, citing recurring losses, dependence on additional financing, and risk of ceasing operations if funding is unavailable.
- ABI said its sole human-interferon supplier had discontinued production. Finding and qualifying a new source, conducting trials, and obtaining regulatory approval could be costly and time-consuming; two of five patents were due to expire in less than seven months, and three in four to seven years. The filing also described supply and cost issues affecting its oral-health product.
- ABI reported that more than $4 million of debt was discharged through bankruptcy reorganization. It also described fresh-start accounting and a reverse stock split as part of the reorganization. No stock was sold in the first nine months of 2015.
- The Yang Group distributed shares to constituent members in September and October 2015. The filing reported Stephen T. Chen’s beneficial ownership at 13.16% after the October distribution and stated that 800,000 Yang Group shares remained held by the group.
- Management reported effective disclosure controls and no known pending legal proceedings as of the report. The company also disclosed risks related to third-party manufacturing and distribution, clinical and regulatory requirements, competition, personnel, and the limited liquidity of its penny-stock shares.
Important facts for investors to verify
- Confirm issuer identity: the supplied filing is for Amarillo Biosciences, Inc., although the request names Ainos, Inc.
- Verify the status, terms, and any subsequent resolution of the overdue $37,811 secured-note installment and other related-party obligations.
- Assess available financing against the stated $1.0 million–$1.6 million need, cash balance, and going-concern warning.
- Check current status of interferon sourcing, product commercialization plans, patent expirations, and regulatory or clinical requirements.
- Review subsequent ownership changes and the impact of shareholder transactions on control and the potential use of reported tax attributes.